Comparative Pharmacology
Head-to-head clinical analysis: ALTAVERA versus KIMIDESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTAVERA versus KIMIDESS.
ALTAVERA vs KIMIDESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
5 mg orally once daily, with or without food.
None Documented
None Documented
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive